J Napier | diabetes.medicinematters.com Skip to main content

Browse topics

Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics

In focus

Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management

Congress coverage

EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions

About us

Medicine Matters Diabetes

EXTENDED SEARCH

Medicine Matters Diabetes

JAVASCRIPT NEEDED

Please enable JavaScript on your browser, so that you can use all features of this website.

INTERNET EXPLORER IS NO LONGER SUPPORTED

Your version of Internet Explorer is no longer supported by this system. Please install one of the following browsers: Microsoft Edge, Safari, Chrome or Firefox

J Napier

Contact

address:: The Action on DMO group, UK; Bayer, Reading, UK

Home
Latest news
Browse topics
In focus
Congress coverage
- EASD 58th Annual Meeting 2022
- The American Diabetes Association 82nd Scientific Sessions
About us

Version: 0.3557.0